Healthy Time

Experience:

Interventional Cardiology
General Cardiology
Cardiovascular research
Cardiac device implants
Valvular Heart Disease
Echocardiography and device optimization
Nuclear Cardiology

Board Certification / Eligibility / Speciality Training Certifications:

Internal Medicine American
Cardiovascular Disease
Interventional Cardiology
Nuclear Medicine
Echocardiography

Fellowships and Memberships:

American Medical Association
American College of Cardiology
American College of Physicians
American Society of Angiography and Intervention
American Socity of Nuclear MedicineAmerican Society of Echocardiography
American Board of Cardiology
Society for CT Coronary Angiography
Ohio State Medical Association
 

Positions and Appointments​:

Cardiology Chief, Mercy St. Vincent Medical Center
Director, Cardiac Services, Mercy St. Vincent Medical Center
Medical Executive Committee, Member at Large
St. Vincent Foundation, Trustee
President and CEO, Toledo Cardiology Consultants, Inc
President, Cardiovascular Mobile Imaging, LLC
President, Midwest Modern Imaging, LLC
President Cardiovascular Research Center
CME Director, NAAMA
Chairman, Cardiology Today Conference
Chairman, American Heart Association Gala (2008 and 2009)
Creator and developer "Time Waits for No One" a patient educational TV minute.
 

Education and Training:

7/95 - 6/96      Interventional Cardiology Fellowship
                        University of Chicago.
                        Chicago, Illinois.

7/92 - 6/95      Clinical Cardiology Fellowship
                        University of Missouri
                        Columbia, Missouri.

7/91 - 6/92      Chief Resident (PGYIII)
                        St. Joseph Mercy Hospital
                        Wayne State University Pontiac, Michigan.

7/89 - 6/91      Internal Medicine Residency
                        St. Joseph Mercy Hospital
                        Wayne State University, Pontiac, Michigan.

2/88 - 5/89      Medical Consultant
                        Medical Rehabilitation Services
                        West Bloomfield, Michigan

1/86 - 2/87     Chief Resident
                       Medical Care Center/Damascus University
                       Damascus, Syria.

9/84 - 2/87     Combined Internal Medicine/Surgery
                       Residency Medical Care Center
                       Damascus, Syria

9/78 - 11/84   Damascus University Faculty of Medicine
                       Damascus, Syria

Publications:
Articles and studies:

Dean J. Kereiakes, Louis A. Cannon, Robert L. Feldman, Jeffrey J. Popma, Raymond Magorien, Robert Whitbourn, Ira M. Dauber, Abram C. Rabinowitz, Michael W. Ball, Barry Bertolet, Ameer Kabour, Michael C. Foster, John C. Wang, Paul Underwood, and Keith D. Dawkins. Clinical and Angiographic Outcomes After Treatment of De Novo Coronary Stenoses With a Novel Platinum Chromium Thin-Strut Stent: Primary Results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) Trial.
J. Am. Coll. Cardiol. published online May 19, 2010;

Ameer Kabour, MD, FACC, FSCAI, and E., Dean Nukta, MD, Facp, FACC, FSCAI:  The Mynx® Vascular Closure Device. Adopting extravascular closure technology  in the  catheterization lab.
Endovascular Today. May, 2009

T. Feldman, T.N. Levin, and A. Kabour,
Percutaneous Transvenous Mitral Commissurotomy Following Carpentier Ring Annuloplasty .
The J of Invasive Cardiology. 1997; 9: 184

A. Kabour,JR. Henegar, JS. Janicki.
Angiotensin II induced myocyte necrosis : role of the angiotensin II receptors
J. Cardiovascular Pharma. 1994;26:547

JS. Janicki, BB. Matsubara, A. Kabour.
Myocardial collagen and its functional role   Book-chapter-28 (Interactive phenomena in the cardiac system)
Adv.Exp Med Biol.1993;346:291

A. Kabour, JR. Henegar, VR. Devineni, JS. Janicki.
Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat
Cardiovascular Research. 1995;29:543

JR. Henegar, A. Kabour, JS. Janicki.
The role of catecholamine in the angiotensin II related myocyte necrosis and vascular damage
Craiovas Research.

A. Kabour,JR. Henegar, JS. Janicki.
Ability of beta blocker to prevent angiotensin II related myocyte necrosis
Circulation.1994.90. 4.part 2. 1712

A. Kabour, VR.Devineni, JR. Henegar, JS. Janicki
Mechanism of angiotensin II related coronary vascular injury in renovascular hypertension
Circulation.1993;88.4, part2.I-634

JS. Janicki, A. Kabour, JR. Henegar.
Ventricular hypertrophy in normal and high renin experimental hypertension Circulation. 1993;88, 4, part2. I-243

A. Kabour, JR. Henegar, JS. Janicki.
The ability of low and high dose angiotensin converting enzyme inhibition to prevent angiotensin II related myocyte necrosis
JACC. 1993;21: 258A

A. Kabour, JR. Henegar, JS. Janicki.
Angiotensin converting enzymes inhibition prevent volume-overload left and right ventricular hypertrophy
JACC. 1993;21.258A

A. Kabour,JR. Henegar, JS. Janicki.
The effect of chronic versus intermittent elevation of plasma angiotensin II on myocyte necrosis
FASEB. J.1993;7: A805

A. Kabour, JR. Henegar, JS, Janicki.
Angiotensin II induced myocyte necrosis: role of AT1 receptors
J.Mol.Cell. Cardiol. 1993;25 (sup III):27

A. Kabour, JR. Henegar, JS. Janicki.
Prevention of myocyte necrosis in renovascular hypertension using the angiotensin converting enzyme inhibition; Lisinopril
J.Mol. Cell.Cardiol.1993;25 (sup III):228

Abstracts:

A.Kabour.JR. Henegar, JS. Janicki.
Ability of beta blocker to prevent AII related myocyte necrosis
67th Scientific Session. AHA, Nov 1994.

A. Kabour, GS. Raviprassad, E. Tjahja, GL.Bower. JS.Janicki.
Myocardial collagen activity during pregnancy in rats
ACP meeting. Lake of the Ozark. 1/95

A. Kabour. JR. Henegar, JS. Janicki.
Mechanism of AII related coronary vascular injury in renovascular hypertension
66th Scientific session, AHA, Nov 1993

A. Kabour.JR. Henegar, JS. Janicki.
Ventricular hypertrophy in normal and high renin experimental hypertension 66th Scientific Session, AHA, Nov 1993.

A. Kabour. JS. Janicki
ACE-Inhibition prevents remote myocyte necrosis secondary to myocardial infarction
Central Society for Clinical Research.
Chicago.  Oct 1993.

A. Kabour,JR. Henegar, JS. Janicki
Ability of beta blocker to prevent AII related myocyte necrosis
Central Society for Clinical Research
Chicago. Oct 1993

A. Kabour,  B. Forum, Z. Turi
Absence of coronary artery disease in patients undergoing coronary angiography:use of a retrospectively derived risk index score.
ACP meeting. Michigan 1992

A. Kabour, FH. Smith.
Effect of dietary low NaCl intake on the microvessel number in rat mesentery
ACP and OHP meeting 1992

A. Kabour, J. Heinsimer.
The impact of clinical trial : in the thrombolytic era
ACP meeting. may.1992

A. Kabour,  B. Bercu.
Bilateral rapid atrial rhythm treated with cardioversion
ACP meeting.May. 1992

Scientific involvement:

Chairman and organizer of
Research investigator for the Taxux 2 study in NW Ohio, 2005
Improve Study, 2007
ACS study, 2007
Research investigator for Boston scientific, 2002-2006
Research investigator for Millennum-Schering Co, 2002-2006
Speaker in different subject for diffrent pharmaceutica and technology companies. Including but not limited to:
Pfize
Merc
Astra zenic
Glaxo Smith Klin
Millennum-Shering
Sherin
Lill
Boston Scientific
Guidan
J & J company / Cordi
Philip
 

Current Research Project / principle Investigation:

 

 

JOMED JOSTENT
IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE IT)
Pfizer PRECISION Trial Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen Or Naproxen- A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Celecoxib With Naproxen and Ibuprofen. 
Double-Blind, Randomized, Globally Conducted Trial Comparing Study Drug with Warfarin for the Prevention of Stroke (Atrial Fibrillation) ARISTOTLE.
Boston Scientific: ION Registry.
Boston Scientific: PLATINUM A Prospective, Randomized, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of up to two De Novo Coronary Artery Lesions
Quintiles/Eli Lilly H7T-MC-TABY: A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (US/NSTEMI) who are Medically Managed The TRILOGY ACS Study
Abbott: XIENCE Registry
Roche /Quintiles NC20971: A randomized, double-blind, placebo-controlled study assessing the effects of R04607381 on cardiovascular mortality and morbidity in clinically stable patients with a recent acute coronary syndrome.
Solvay Pharmaceuticals / Quintiles S320.2.011 A Double-blind, Placebo-controlled, Randomized, Dose-finding Study of SLV320, a Selective A1 Adenosine Receptor Antagonist, to Evaluate the Effect on Renal Function and Safety in Subjects Hospitalized with Acute Decompensated Heart Failure and Renal Dysfunction.
CV Therapeutics Inc CVT 3041 An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Women
Medtronics SLS System Longevity Study.
Medtronics StarFix Left Ventricular Chronic Performance Study
Medtronics 4196
Abbott Cardiovascular Systems, Inc. 08-383 SPIRIT Small Vessel Registry (SPIRIT SV) Clinical Trial: A Clinical Evaluation of the 2.25 mm XIENCE V
Abbott SPIRIT PRIME 06-373 A Clinical Evaluation of the XIENCE PRIME
Taxus PERSEUS - A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS
APPRAISE
BOREALIS-AF: A multicenter, randomized, double-blind, assessor-blin, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation.
Astella Pharma Global Development, Inc/PPD ISN6517-CL-0020 A Phase 3b, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients with Recent Onset Symptomatic Atrial Fibrillation.
Chronic CHF Study.
DAPT A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions.